Difference between revisions of "NovoTTF-100A system (Optune)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "Category:Device index" to "Category:Devices")
m
Line 3: Line 3:
 
<br>Route: external portable device
 
<br>Route: external portable device
 
<br>Extravasation: n/a
 
<br>Extravasation: n/a
 +
 +
==Diseases for which it is used==
 +
*[[Glioblastoma]]
  
 
==Patient drug information==
 
==Patient drug information==
Line 9: Line 12:
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
−
*4/8/2011: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm251669.htm FDA approved] "to treat adults with [[Central nervous system (CNS) cancer|glioblastoma multiforme (GBM)]] that recurs or progresses after receiving chemotherapy and radiation therapy."<ref>[http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm254480.htm NovoTTF-100A system FDA overview of information]</ref>
+
*4/8/2011: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm251669.htm FDA approved] "to treat adults with [[Glioblastoma|glioblastoma multiforme (GBM)]] that recurs or progresses after receiving chemotherapy and radiation therapy."<ref>[http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm254480.htm NovoTTF-100A system FDA overview of information]</ref>
−
*10/5/2015: [http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm465744.htm FDA approved expanded indication] "as a treatment for adult patients (22 years of age or older) with histologically-confirmed [[Central nervous system (CNS) cancer|glioblastoma multiforme (GBM)]]...for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery and completion of radiation therapy together with concomitant standard of care chemotherapy."
+
*10/5/2015: [http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm465744.htm FDA approved expanded indication] "as a treatment for adult patients (22 years of age or older) with histologically-confirmed [[Glioblastoma|glioblastoma multiforme (GBM)]]...for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery and completion of radiation therapy together with concomitant standard of care chemotherapy."
  
 
==Also known as==
 
==Also known as==
−
NovoTTF-100A device, PMA P100034/S013
+
*'''Code name:''' PMA P100034/S013
 +
*'''Brand name:''' NovoTTF-100A device
  
 
==References==
 
==References==
Line 19: Line 23:
  
 
[[Category:Devices]]
 
[[Category:Devices]]
 +
[[Category:Glioblastoma medications]]

Revision as of 00:10, 23 August 2018

General information

Class/mechanism: External portable device which delivers electric tumor treating fields (TTFields) via insulated transducer arrays placed on the patient's skin close to glioblastoma multiforme (GBM) tumors. TTFields affect dividing cells by two main mechanisms. First, they disrupt microtubule spindle formation during anaphase, in which tubulin, a highly electrically polar molecule, normally forms polymers. Exposure to TTFields prevents tubulin from being able to align properly and promotes depolymerization of mitotic spindles. Second, the TTFields disrupt the cleavage plane between the two daughter cells during late telophase. These actions halt cell division, cause abnormal spindle formation, disrupt regular chromosome separation, and result in apoptosis.[1][2][3][4][5][6][7]
Route: external portable device
Extravasation: n/a

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 4/8/2011: FDA approved "to treat adults with glioblastoma multiforme (GBM) that recurs or progresses after receiving chemotherapy and radiation therapy."[10]
  • 10/5/2015: FDA approved expanded indication "as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM)...for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery and completion of radiation therapy together with concomitant standard of care chemotherapy."

Also known as

  • Code name: PMA P100034/S013
  • Brand name: NovoTTF-100A device

References

  1. ↑ NovoTTF-100A system (Optune) FDA summary of safety and effectiveness data (SSED)
  2. ↑ NovoTTF-100A system (Optune) FDA summary of safety and effectiveness data (SSED) (locally hosted backup)
  3. ↑ NovoTTF-100A FDA neurological device information
  4. ↑ NovoTTF-100A FDA neurological device information (locally hosted backup)
  5. ↑ NovoTTF-100A manufacturer's website
  6. ↑ FDA medical device page
  7. ↑ Optune manufacturer's website
  8. ↑ NovoTTF-100A device (Optune) instructions for use
  9. ↑ NovoTTF-100A FDA neurological device information PDF pages 208-259
  10. ↑ NovoTTF-100A system FDA overview of information
Retrieved from "https://hemonc.org/w/index.php?title=NovoTTF-100A_system_(Optune)&oldid=30643"